BioSpace News Archive

Presentation today during Joint ACTRIMS-ECTRIMS Meeting at MSVirtual2020 Results provide first clinical evidence demonstrating catalytic effects of CNM-Au8 in multiple sclerosis and Parkinson’s disease patients

With the noticeable surge in the incidence rate of human immunodeficiency virus -1 infection, the market for HIV therapeutics market is gaining remarkable momentum across the world.

Transparency Market Research has published a new report titled, ‘Mechanical Ventilators Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, responds to LAVVAN, Inc.'s (LAVVAN) press release related to its commencement of a lawsuit against Amyris, Inc. (Amyris) for patent

According to the report, the global vascular stents market was valued at US$ 7.6 Bn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2027.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that BioComo, co-developer of MediciNova’s SARS-CoV-2 vaccine for COVID-19, announced that its Respiratory Syncytial virus vaccine using BC-PIV technology induced high neutralizing antibodies in mice.

Spero Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 4,785,000 shares of its common stock and 3,215,000 shares of its non-voting Series D Convertible Preferred Stock.

Welltower® Inc. (NYSE: WELL) announced today that it will participate in the Evercore ISI Real Estate Conference to be held on September 11 , 2020. In conjunction with the conference, Welltower has issued the following presentation which can be found at: https://welltower.com/evercore-isi-real-estate-conference

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.